Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nulabeglogene autogedtemcel - LENZ Therapeutics

Drug Profile

Nulabeglogene autogedtemcel - LENZ Therapeutics

Alternative Names: Autologous CD34+ Hematopoietic Stem Cells - LENZ Therapeutics; GPH-101 - Graphite Bio; nula-cel

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Kamau Therapeutics
  • Class Antianaemics; Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Sickle cell anaemia

Most Recent Events

  • 21 Mar 2024 LENZ Therapeutics has merged with Graphite Bio to form LENZ Therapeutics
  • 31 Jan 2024 Kamau Therapeutics reinitiates enrollment in the phase-I/II CEDAR trial in Sickle cell anaemia (In adolescents, In adults) in USA (IV) (NCT04819841)
  • 08 Dec 2023 Kamau Therapeutics enters option to acquire agreement with Graphite Bio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top